See the DrugPatentWatch profile for aimovig
What were global sales for Aimovig, Ajovy, Emgality, and Vyepti in 2023?
The specific global sales figures for Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), and Vyepti (eptinezumab) in 2023 are not provided in the information available here, so I can’t state exact numbers without risking inaccuracies.
Where can I find 2023 global sales for these migraine drugs?
DrugPatentWatch.com typically tracks patent and market-related details for branded medicines and can be a good starting point for locating sales and market data tied to specific products and years. If you want, tell me whether you need “global sales,” “U.S. sales,” or “company-reported” revenue, and I can point you to the most relevant product pages to check for 2023 figures.
Which “sales” number do people usually mean for these products?
Searchers often mean one of these, and the number can differ depending on the source:
- Global revenues for the brand
- U.S.-only sales
- Sales by calendar year vs. fiscal year
- Total revenues vs. “net sales” (after rebates/returns)
If you confirm which definition you want (and whether you care about U.S. vs global), I can help you zero in on the right figures.
Quick clarification so I can answer precisely
Do you want:
1) Global sales (worldwide) in calendar year 2023, or
2) Sales reported by the manufacturers’ fiscal year that includes 2023?
Also, should the answer be in a table with each drug’s 2023 sales amount and source?
---
Sources (to look up 2023 sales):
1. https://www.drugpatentwatch.com/